European Neuropsychopharmacology最新文献

{"title":"Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study","authors":"Eduard Vieta ,&nbsp;Nahida Ahmed ,&nbsp;Celso Arango ,&nbsp;Anthony J. Cleare ,&nbsp;Koen Demyttenaere ,&nbsp;Markus Dold ,&nbsp;Tetsuro Ito ,&nbsp;Yerkebulan Kambarov ,&nbsp;Stephanie Krüger ,&nbsp;Pierre-Michel Llorca ,&nbsp;Roger S. McIntyre ,&nbsp;Gabriele Sani ,&nbsp;Christian von Holt ,&nbsp;Benoit Rive","doi":"10.1016/j.euroneuro.2024.12.013","DOIUrl":"10.1016/j.euroneuro.2024.12.013","url":null,"abstract":"<div><div>Patients with treatment resistant depression (TRD) experience a greater negative impact on their functioning and productivity at home and in the workplace versus treatment-responsive patients. Here, we report the effects of esketamine nasal spray (NS) versus quetiapine extended release (XR) on functioning, work productivity and activity impairment. ESCAPE‑TRD (NCT04338321) was a 32-week randomised, open‑label, rater‑blinded, active‑controlled phase IIIb study comparing the efficacy and safety of esketamine NS versus quetiapine XR, both alongside an ongoing selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor (SSRI/SNRI), in patients with TRD. Patient functioning was assessed via the Sheehan Disability Scale (SDS; functional remission ≤6). Absenteeism, presenteeism, work productivity loss and activity impairment over time were assessed using the Work Productivity and Activity Impairment: Depression (WPAI:D) questionnaire. Results were cumulated over the entire study duration. Esketamine NS-treated patients (<em>N</em> = 336) experienced 43.2 % more weeks with functional remission versus quetiapine XR-treated patients (<em>N</em> = 340) over the 32-week study period (difference: 2.0 weeks [95 % CI: 0.7, 3.3]; <em>p</em> = 0.0023 [ANCOVA models]). Up to Week 32, esketamine NS-treated patients experienced an 11.9 % reduction in productivity loss due to absenteeism (difference: −1.1 weeks [95 % CI: −2.9, 0.7]; <em>p</em> = 0.2285) and a 14.2 % reduction in overall work productivity loss (difference: –2.3 weeks, 95 % CI: [–3.9, –0.7] <em>p</em> = 0.0045) versus quetiapine XR-treated patients, based on mixed models for repeated measures. Patients receiving esketamine NS experienced greater improvements in functioning and productivity over 32 weeks versus quetiapine XR. These improvements demonstrate the clinical and functional benefit of treatment with esketamine NS for patients with TRD.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 29-39"},"PeriodicalIF":6.1,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143372043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-stratified mortality estimates in people with schizophrenia: A systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia","authors":"Marco Solmi ,&nbsp;Giovanni Croatto ,&nbsp;Nicholas Fabiano ,&nbsp;Stanley Wong ,&nbsp;Arnav Gupta ,&nbsp;Michele Fornaro ,&nbsp;Lynne Kolton Schneider ,&nbsp;S. Christy Rohani-Montez ,&nbsp;Leanne Fairley ,&nbsp;Nathalie Smith ,&nbsp;István Bitter ,&nbsp;Philip Gorwood ,&nbsp;Heidi Taipale ,&nbsp;Jari Tiihonen ,&nbsp;Samuele Cortese ,&nbsp;Elena Dragioti ,&nbsp;Ebba Du Rietz ,&nbsp;Rene Ernst Nielsen ,&nbsp;Joseph Firth ,&nbsp;Paolo Fusar-Poli ,&nbsp;Christoph U. Correll","doi":"10.1016/j.euroneuro.2024.11.001","DOIUrl":"10.1016/j.euroneuro.2024.11.001","url":null,"abstract":"<div><div>The differential influence of sex on premature mortality in schizophrenia is unclear. This study assessed the differences in all-cause and specific cause mortality risks in people with schizophrenia compared to several control groups stratified by sex. We conducted a PRISMA 2020-compliant systematic review and random-effects meta-analysis of cohort studies assessing mortality relative risk (RR) for people with schizophrenia, comparing by sex. We measured publication bias and conducted a quality assessment through the Newcastle-Ottawa scale. We meta-analyzed 43 studies reporting on 2,700,825 people with schizophrenia. Both males and females with schizophrenia had increased all-cause mortality vs. comparison groups (males, RR=2.62, 95%CI 2.35–2.92; females, RR=2.56, 95%CI 2.27–2.87), suicide (males, RR=9.02, 95%CI 5.96–13.67; females, RR=12.09, 95%CI 9.00–16.25), and natural cause mortality (males, RR=2.11, 95%CI 1.88–2.38; females, RR=2.14, 95%CI 1.93–2.38). No statistically significant differences in sex-dependent mortality risk emerged. There was an age-group-dependent increased mortality risk in females &lt; 40 years vs. &gt;/=40 years old (RR=4.23/2.17), and significantly higher risk of death due to neurological disorders (dementia) in males vs. females (RR=5.19/2.40). Increased mortality risks were often associated with specific modifiable risk factors. The increased mortality risk did not improve over time, calling for more studies to identify modifiable factors, and for better physical healthcare for males and females with schizophrenia.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 56-66"},"PeriodicalIF":6.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Classical psychedelics in therapy: Essential psychotherapy or minimal support?","authors":"Gitte M Knudsen","doi":"10.1016/j.euroneuro.2025.01.004","DOIUrl":"10.1016/j.euroneuro.2025.01.004","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 27-28"},"PeriodicalIF":6.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dilemmas in psychedelic medicine: From ethics to regulation and equity","authors":"Albino J. Oliveira-Maia ,&nbsp;Carolina Seybert","doi":"10.1016/j.euroneuro.2024.11.003","DOIUrl":"10.1016/j.euroneuro.2024.11.003","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 67-68"},"PeriodicalIF":6.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examining the impact of comorbid posttraumatic stress disorder on ketamine's real-world effectiveness in treatment-resistant depression","authors":"Danica E. Johnson ,&nbsp;Nelson B. Rodrigues ,&nbsp;Sydney Weisz ,&nbsp;Noah Chisamore ,&nbsp;Erica S. Kaczmarek ,&nbsp;David C.J. Chen-Li ,&nbsp;Zoe Doyle ,&nbsp;J Don Richardson ,&nbsp;Rodrigo B. Mansur ,&nbsp;Roger S. McIntyre ,&nbsp;Joshua D. Rosenblat","doi":"10.1016/j.euroneuro.2024.11.008","DOIUrl":"10.1016/j.euroneuro.2024.11.008","url":null,"abstract":"<div><div>Depression with comorbid posttraumatic stress disorder (PTSD) is associated with more severe symptoms and a reduced response to traditional treatments. Although ketamine shows promise as a rapid-acting antidepressant for treatment-resistant depression (TRD), its effectiveness in patients with comorbid PTSD remains underexplored. Therefore, we conducted a retrospective analysis of 134 patients from the Canadian Rapid Treatment Center of Excellence to compare the effectiveness of four ketamine infusions (0.5–0.75 mg/kg) in reducing symptoms of depression and PTSD in TRD patients with and without comorbid PTSD.</div><div>A repeated-measures linear mixed model was used to evaluate the impact of comorbid PTSD on ketamine's antidepressant effectiveness, measured by the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16). Paired samples <em>t</em>-tests were used to assess changes in PTSD symptoms, measured by the PTSD Checklist for DSM-5 (PCL-5). We found a significant main effect of time on QIDS-SR16 scores, F(4, 209.32) = 36.67, <em>p</em> &lt; 0.001, but no significant group-by-time interaction (<em>p</em> = 0.895), suggesting that comorbid PTSD did not impact the antidepressant effectiveness of ketamine. Significant improvements in PTSD symptoms were observed in overall PCL-5 scores, t(66) = 6.66, <em>p</em> &lt; 0.001, and across all PCL-5 symptom clusters with moderate to large effect sizes.</div><div>In a real-world sample of TRD patients, ketamine was effective in reducing symptoms of depression and PTSD, regardless of PTSD comorbidity. These findings highlight ketamine's potential as a novel intervention for a patient population that is frequently non-responders to conventional treatments. Future randomized controlled trials should explore mediating factors of improvement and long-term effects.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 69-77"},"PeriodicalIF":6.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential effects of Xanomeline-trospium chloride on positive and negative symptoms in Schizophrenia: The role of dose","authors":"Tzu-Yen Hung ,&nbsp;Yo-Chia Hsu ,&nbsp;Yang-Chieh Brian Chen ,&nbsp;Chih-Wei Hsu","doi":"10.1016/j.euroneuro.2025.01.005","DOIUrl":"10.1016/j.euroneuro.2025.01.005","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 22-23"},"PeriodicalIF":6.1,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143159759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of antidepressant-like effect of imipramine, fluoxetine and ketamine in the forced swim test in mice: How much standardization does a positive control require?","authors":"Marcela Verginia de Medeiros ,&nbsp;Eduardo Antonio Rosa ,&nbsp;Gabriela Vissintainer ,&nbsp;Cilene Lino de Oliveira ,&nbsp;Bruno Jacson Martynhak","doi":"10.1016/j.euroneuro.2024.12.012","DOIUrl":"10.1016/j.euroneuro.2024.12.012","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 24-26"},"PeriodicalIF":6.1,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease continuum centered on Parkinson's disease","authors":"Ming Zheng","doi":"10.1016/j.euroneuro.2025.01.002","DOIUrl":"10.1016/j.euroneuro.2025.01.002","url":null,"abstract":"<div><div>Parkinson’s disease (PD), once viewed as a neurodegenerative disorder, is now increasingly recognized as part of a broader disease continuum, intricately linked to comorbidities across various organ systems. This study provides a snapshot of the disease continuum centered on PD, using a disease-wide association study (DWAS) involving 392,423 individuals—including 4,235 PD cases. This DWAS identifies disease clusters of PD comorbidities across the musculoskeletal, circulatory, digestive, and respiratory systems. Moreover, comorbidities were classified based on their temporal relationship to PD diagnosis: pre-PD comorbidities, such as hypertension and autoimmune disorders, may act as risk factors of PD onset, while post-PD comorbidities, including Alzheimer’s disease and renal disorders, highlight the systemic consequences of PD progression. These findings emphasize the critical need for early detection and intervention to manage comorbidities and potentially delay PD onset. Furthermore, this study advocates for integrated diagnostic and therapeutic strategies targeting shared risk factors, advancing a precision-medicine approach to improve patient care and long-term management of PD.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 19-21"},"PeriodicalIF":6.1,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low dose oral ketamine treatment on post-traumatic stress disorder (PTSD) (OKTOP): An open-label pilot study","authors":"Bonnie L. Quigley ,&nbsp;Adem T. Can ,&nbsp;Megan Dutton ,&nbsp;Cyrana C. Gallay ,&nbsp;Grace Forsyth ,&nbsp;Monique Jones ,&nbsp;Fiona Randall ,&nbsp;Trish Wilson ,&nbsp;Jim Lagopoulos ,&nbsp;Daniel F. Hermens","doi":"10.1016/j.euroneuro.2025.01.003","DOIUrl":"10.1016/j.euroneuro.2025.01.003","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 17-18"},"PeriodicalIF":6.1,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary evidence should be treated as such: Response to “Is creatine useful as adjuvant in cognitive-behavioural therapy for depression?”","authors":"Riccardo De Giorgi ,&nbsp;Nima Norbu Sherpa ,&nbsp;Edoardo Giuseppe Ostinelli","doi":"10.1016/j.euroneuro.2024.12.015","DOIUrl":"10.1016/j.euroneuro.2024.12.015","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 15-16"},"PeriodicalIF":6.1,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}